Stoke Therapeutics, Inc.
STOK- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001623526
In the last 90 days, Stoke Therapeutics, Inc. insiders filed 0 open-market purchases and 6 sales; 197 institutions reported holding it in 13F filings for Q2 2026, worth $2.49B in total; no superinvestor holds it.
13F holders, Q2 2025
Institutional positions in Stoke Therapeutics, Inc. as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 134
- +8 vs. Q1 2025
- Shares held
- 65.5M
- +2.16M (+3.4%) vs. Q1 2025
- Total value
- $744.0M
- +$322.4M (+76.5%) vs. Q1 2025
- New holders
- 24
- 51 more added
- Sold out
- 16
- 33 more reduced
Compare with Q1 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting STOK on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 197 | $2.49B |
| Q1 2026 | 198 | $2.31B |
| Q4 2025 | 183 | $2.13B |
| Q3 2025 | 151 | $1.57B |
| Q2 2025 | 134 | $744.0M |
| Q1 2025 | 126 | $421.6M |
| Q4 2024 | 130 | $640.4M |
| Q3 2024 | 118 | $715.5M |
| Q2 2024 | 115 | $828.5M |
| Q1 2024 | 103 | $731.7M |
| Q4 2023 | 81 | $236.9M |
| Q3 2023 | 97 | $173.1M |
| Q2 2023 | 100 | $494.8M |
| Q1 2023 | 97 | $371.8M |
| Q4 2022 | 107 | $371.8M |
| Q3 2022 | 105 | $544.4M |
| Q2 2022 | 92 | $569.4M |
| Q1 2022 | 99 | $870.6M |
| Q4 2021 | 94 | $849.6M |
| Q3 2021 | 90 | $492.4M |
| Q2 2021 | 97 | $680.3M |
| Q1 2021 | 106 | $1.49B |
Institutions, Q2 2025
Shares, value and share of portfolio for each institution holding Stoke Therapeutics, Inc.; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Barclays PLC | 139,900 | $1.59M | 0.00% | +71,539+104.6% | Added |
| Royal Bank of Canada | 144,064 | $1.64M | 0.00% | +144,016+300,033.3% | Added |
| Schonfeld Strategic Advisors LLC | 174,714 | $1.98M | 0.01% | −160,646−47.9% | Reduced |
| Birchview Capital, LP | 210,000 | $2.38M | 2.37% | −50.0% | Reduced |
| Cormorant Asset Management, LP | 254,161 | $2.88M | 0.21% | 00.0% | Unchanged |
| Charles Schwab Investment Management Inc | 340,779 | $3.87M | 0.00% | +30,472+9.8% | Added |
| UBS Group AG | 352,715 | $4.00M | 0.00% | +180,884+105.3% | Added |
| Erste Asset Management GmbH | 396,000 | $4.51M | 0.04% | 00.0% | Unchanged |
| Northern Trust Corp | 423,554 | $4.81M | 0.00% | +76,890+22.2% | Added |
| Tang Capital Management LLC | 500,000 | $5.67M | 0.29% | 00.0% | Unchanged |
| DAFNA Capital Management LLC | 501,972 | $5.70M | 1.57% | +57,974+13.1% | Added |
| Granahan Investment Management Inc | 532,413 | $6.04M | 0.25% | −128,017−19.4% | Reduced |
| Assenagon Asset Management S.A. | 537,973 | $6.11M | 0.01% | −421,630−43.9% | Reduced |
| Bank of America Corp | 548,090 | $6.22M | 0.00% | +15,206+2.9% | Added |
| Opaleye Management Inc. | 562,120 | $6.38M | 1.29% | +262,120+87.4% | Added |
| CI Private Wealth, LLC | 659,834 | $7.49M | 0.01% | +659,834 | New |
| Dimensional Fund Advisors LP | 673,884 | $7.65M | 0.00% | +9,149+1.4% | Added |
| MPM Oncology Impact Management LP | 789,698 | $8.96M | 1.55% | +95,710+13.8% | Added |
| Polar Capital Holdings Plc | 883,646 | $10.0M | 0.05% | +883,646 | New |
| Geode Capital Management, LLC | 972,921 | $11.0M | 0.00% | +70,935+7.9% | Added |
| Goldman Sachs Group Inc | 1,301,381 | $14.8M | 0.00% | −360,658−21.7% | Reduced |
| State Street Corp | 1,487,156 | $16.9M | 0.00% | −88,127−5.6% | Reduced |
| Siren, L.L.C. | 2,247,347 | $25.5M | 1.32% | 00.0% | Unchanged |
| Marshall Wace, LLP | 2,300,554 | $26.1M | 0.03% | +168,771+7.9% | Added |
| Vanguard Group Inc | 2,946,258 | $33.4M | 0.00% | +162,056+5.8% | Added |
| Toronto Dominion Bank | 3,173,258 | $36.0M | 0.08% | 00.0% | Unchanged |
| Skorpios Trust | 3,256,181 | $37.0M | 99.62% | −3,650,000−52.9% | Reduced |
| Morgan Stanley | 3,573,976 | $40.6M | 0.00% | −16,849−0.5% | Reduced |
| Redmile Group, LLC | 4,375,931 | $49.7M | 5.29% | −110,050−2.5% | Reduced |
| Baker Bros. Advisors LP | 4,633,838 | $52.6M | 0.51% | 00.0% | Unchanged |
| RTW Investments, LP | 5,123,525 | $58.2M | 0.83% | 00.0% | Unchanged |
| Lynx1 Capital Management LP | 5,404,674 | $61.3M | 17.72% | +112,745+2.1% | Added |
| BlackRock, Inc. | 5,924,567 | $67.2M | 0.00% | +62,131+1.1% | Added |
| FMR LLC | 7,412,982 | $84.1M | 0.00% | +4,871,045+191.6% | Added |
| Checkpoint Capital L.P. | 0 | $0 | 0.00% | −730,717−100.0% | Sold out |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −178,300−100.0% | Sold out |
| Trexquant Investment LP | 0 | $0 | 0.00% | −86,140−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −40,181−100.0% | Sold out |
| Graham Capital Management, L.P. | 0 | $0 | 0.00% | −36,087−100.0% | Sold out |
| Dauntless Investment Group, LLC | 0 | $0 | 0.00% | −28,600−100.0% | Sold out |
| Net Worth Advisory Group | 0 | $0 | 0.00% | −20,741−100.0% | Sold out |
| Mesirow Financial Investment Management, Inc. | 0 | $0 | 0.00% | −15,779−100.0% | Sold out |
| Corebridge Financial, Inc. | 0 | $0 | 0.00% | −17,600−100.0% | Sold out |
| Freestone Grove Partners LP | 0 | $0 | 0.00% | −14,776−100.0% | Sold out |
| Axq Capital, LP | 0 | $0 | 0.00% | −14,600−100.0% | Sold out |
| Fox Run Management, L.L.C. | 0 | $0 | 0.00% | −13,780−100.0% | Sold out |
| Covestor Ltd | 0 | $0 | 0.00% | −2,417−100.0% | Sold out |
| Coldstream Capital Management Inc | 0 | $0 | 0.00% | −55−100.0% | Sold out |
| Parkside Financial Bank & Trust | 0 | $0 | 0.00% | −50−100.0% | Sold out |
| Parallel Advisors, LLC | 0 | $0 | 0.00% | −24−100.0% | Sold out |